RISE UP
Gabatar da RISE UP, SABON binciken lafiya don auna raɗaɗin ciwo da ƙarancin jini a ciwon sikila
RISE UP (2021‑001674‑34) rukunin 2/3 ne, na binciken kiwon lafiya mai sakayayyen tsari ruɓi biyu, gaurayayye, wanda ya ƙunshi maganin da ba shi da sinadarin waraka a cikinsa.1
Wannan binciken lafiyan zai bincika inganci da amincin mitapivat a wajen maganin ciwon sikila wa mahalarta masu shekaru 16 zuwa sama.1
Bincike ya nuna cewa fiye da rabin majinyata za su halarci binciken lafiya idan jami’an kiwon lafiyarsu sun tattauna da su.2
TSARIN BINCIKEN LAFIYA NA RISE UP1
RUKUNI NA 3 (Ana Kan Shiga)
BID=sau biyu a rana; Hb=halittan jini.
MUHIMMAN ABUBUWAN DA KE BA DA DAMAR SHIGA1
- Shekaru 16 zuwa sama, wanda tarihi ya nuna sun taɓa yin ciwon sikila (HbSS, HbSC, HbS/β0 thalassemia, Hb/β+ thalassemia, ko kuma wasu nau’ukan ciwon sikila)
- A ƙalla tashin ciwon sikila sau 2 ko kuma yawan da bai haura sau 10 ba a cikin watanni 12 da suka wuce kafin a nema izini kafin samun amincewar mai jinyai
- Wanda ke cikin rukunin tsananin ciwo, matsanancin ciwon ƙirji, matsalan tashin gaba, ko motsawan hanta ko saifa
- Idan ana kan shan hydroxyurea, tsarin shan hydroxyurea ɗin dole ya zama ba fashi na tsawon a ƙalla kwanaki 90 kafin a fara binciken laluɓe cikin duhu
MUHIMMAN ABUBUWAN DA KE HANA SHIGA 1
- Juna biyu ko shayarwa
- Wanda ake wa ƙarin jini a-kai-a-kai
- Mai ciwon hanta, tsananin ciwon hanta, ciwon maɗaci ko ciwon ƙoda mai tsanani
- Wanda aka taɓa yi wa aikin ƙwayan halitta ko wanda aka taɓa yi wa dashen ɓargo ko ƙashi
- Wanda yake kan shan voxelotor, crizanlizumab ko L-glutamine
- Wanda yake kan karɓan kulawa ta jinyan ciwon hanta
- Shan magani mai rage CYP3A4/5 ko mai saka CYP3A4
FARA AIKIN PK YANA TAIMAKA WA LAFIYAN JINI
Mitapivat — maganin binciken RISE UP — ya kasance na bincike ne, na sha ne, sannan mai saka sinadarin PK aiki ne1,3
Fara aikin sinadarin PK, zai iya inganta lafiya, ƙarfi da tsawon ran ƙwayoyin jini (RBC) ga majinyata masu fama da ƙarancin jini1
- Ƙara samar da ƙarfi na ATP, yana taimakawa wajen ba da ƙarfiN da RBC ke buƙata
- Rage 2,3-DPG wanda yake ƙaro iskar oksijin wa jini, hakan yakan rage matsalar cutar sikila
- Yana dawwamar da ƙwayoyi garkuwar jiki, wanda hakan yana rage mutuwar ƙwayoyin jini
YI SHIRI DOMIN WANI RUKUNIN BINCIKEN RISE UP NA GABA
Samu ƙarin bayani game da binciken RISE UP, ciki har da cikakken bayani game da yadda ake shiga, da dukkannin manufofin binciken, da muhamman abubuwan da ke ba da damar shiga da waɗanda ke hana shiga. Daga nan sai ku yi magana da majinyatanku da suka cancanci shiga dangane da binciken.
Idan kana da tambayoyi, tura saƙon imel ga:
medinfo@agios.com (Amurka)
ex-usmedinfo@agios.com (wajen Amurka)
Manazarta:
1. Bayanai a kan fayil. Agios Pharmaceuticals, Inc.
2. Research!America. Zaɓen ra'ayin jama'a na ƙasa. Yuli 2017. An shiga ranar 18 ga watan October, 2023. https://www.researchamerica.org/wp-content/uploads/2022/07/July2017ClinTrialMinorityOversamplesPressReleaseSlidesFINAL_0-1.pdf
3. Howard J, Kuo KHM, Oluyadi A, et al. Rukunin laluɓe a duhu na 2/3, makanta-biyu, sakayayyen bincike mai ruɓi biyu, mitapivat na majinyata masu ciwon sikila. Blood. 2021;138(suppl 1):3109.
